Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. An intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii.
The investigators designed a randomized control study, which enroll adults diagnosed with COPD. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated.
It is well known that some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. In the previous study, the investigators found that an intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii. However, the effect of PHGG supplement on compositional and functional properties of the human microbiota with COPD still remains unclear.
In this proposal, the investigators designed a randomized control study, which enroll adults diagnosed with COPD. The investigators will review their past medical records and related image and lung function test. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated. In the future, it may be used to investigate and analyze the change of microbiota and metabolome, then develop possible treatment options of COPD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COPD with PHGG | Experimental | COPD patient PHGG 5g/day for 1 month |
|
| COPD without PHGG | No Intervention | COPD patient without PHGG 5g/day for 1 month | |
| Healthy with PHGG | Active Comparator | Healthy PHGG 5g/day for 1 month |
|
| Healthy without PHGG | No Intervention | Healthy without PHGG 5g/day for 1 month |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Partially Hydrolyzed Guar Gum (PHGG) | Dietary Supplement | Partially Hydrolyzed Guar Gum 5 gram/day for 1 month |
|
| Measure | Description | Time Frame |
|---|---|---|
| Modified Medical Research Council Dyspnea Scale (mMRC) | change of mMRC scale, 0 the best, 4 the worst | after PHGG 5 gram/day for 1 month |
| COPD Assessment Test (CAT) | change of CAT (0 the best, 40 the worst) | after PHGG 5 gram/day for 1 month |
| St. George's Respiratory Questionnaire (SGRQ) | change of SGRQ score, 0 the best, 100 the worst | after PHGG 5 gram/day for 1 month |
| FEV1 | change of FEV1 | after PHGG 5 gram/day for 1 month |
| FEV1% | change of FEV1% | after PHGG 5 gram/day for 1 month |
| FVC | change of FVC | after PHGG 5 gram/day for 1 month |
| FVC% | change of FVC% | after PHGG 5 gram/day for 1 month |
| FEV1/FVC% | change of FEV1/FVC% | after PHGG 5 gram/day for 1 month |
| FEV3 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yen-Liang Kuo, MD | Contact | 886-2-85128888 | 22030 | pforcekuo@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Chia-Chen Lu, PhD | Department of Respiratory Therapy, College of Medicine, Fu-Jen Catholic University, Taiwan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yen-Liang Kuo | Recruiting | New Taipei City | 24205 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D003141 | Communicable Diseases |
| D012140 | Respiratory Tract Diseases |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
change of FEV3
| after PHGG 5 gram/day for 1 month |
| FEV3% | change of FEV3% | after PHGG 5 gram/day for 1 month |
| FEV3/FVC% | change of FEV3/FVC% | after PHGG 5 gram/day for 1 month |
| MMEF | change of MMEF | after PHGG 5 gram/day for 1 month |
| MMEF% | change of MMEF% | after PHGG 5 gram/day for 1 month |
| PEF | change of PEF | after PHGG 5 gram/day for 1 month |
| PEF% | change of PEF% | after PHGG 5 gram/day for 1 month |
| blood cytokine | change of blood cytokine | after PHGG 5 gram/day for 1 month |
| Microbiota of stool | change of stool microbiota contribution | after PHGG 5 gram/day for 1 month |
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |